Teva Wins One, Loses One In Patent Challenge Appeals At The Federal Circuit
Executive Summary
P&G's Actonel patent ruled valid: The U.S. Court of Appeals for the Federal Circuit rejected Teva's claims that the patent covering the active ingredient in Actonel (risedronate) was obvious and thus invalid. The court upheld a lower court decision that the unexpected results of the drug's potency and toxicity rebut Teva's claim that it was obvious to develop risedronate based on its similarity to another compound. P&G markets the osteoporosis drug in collaboration with Sanofi-Aventis. Actonel had more than $1 billion sales in 2008. The composition patent extends through June 2014 with the pediatric extension P&G received last month
You may also be interested in...
News Roundup: Drug Makers Take Steps To Minimize Impact Of Generics
Wyeth, King update investors on generic Protonix, Skelaxin, while Ranbaxy wins tentative ANDA approval of Nexium generics.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials